Justin Carrico, Claire E Mellott, Sandra E Talbird, André Bento-Abreu, Barbara Merckx, Jessica Vandenhaute, Damia Benchabane, Nicolas Dauby, Olivier Ethgen, Philippe Lepage, Jeroen Luyten, Marc Raes, Steven Simoens, Marc Van Ranst, Amanda Eiden, Mawuli K Nyaku, Goran Bencina
OBJECTIVE: We evaluated the public health impact and return on investment of Belgium's pediatric immunization program (PIP) from both healthcare-sector and societal perspectives. METHODS: We developed a decision analytic model for 6 vaccines routinely administered in Belgium for children aged 0-10 years: DTaP-IPV-HepB-Hib, DTaP-IPV, MMR, PCV, rotavirus, and meningococcal type C. We used separate decision trees to model each of the 11 vaccine-preventable pathogens: diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, measles, mumps, rubella, Streptococcus pneumoniae , rotavirus, and meningococcal type C; hepatitis B was excluded because of surveillance limitations...
2023: Frontiers in Public Health